CMRX - Chimerix, Inc.
5.04 0.00 (0.00%)
After hours: 4:47PM EDT
| Previous Close | 4.99 |
| Open | 5.01 |
| Bid | 3.50 x 500 |
| Ask | 6.08 x 400 |
| Day's Range | 4.96 - 5.06 |
| 52 Week Range | 4.17 - 6.24 |
| Volume | 69,130 |
| Avg. Volume | 194,909 |
| Market Cap | 240.168M |
| Beta | 1.92 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.51 |
| Earnings Date | May 7, 2018 - May 11, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.75 |
- GlobeNewswire•22 days ago
Chimerix to Present at the H.C. Wainwright Annual Global Life Sciences Conference
DURHAM, N.C., April 02, 2018-- Chimerix, a biopharmaceutical company developing novel antivirals for the growing population of immunocompromised patients, today announced that Garrett Nichols, M.D., M.S., ...
- American City Business Journals•25 days ago
Look what Triangle woman just became chairwoman of a $250M company
Amid pushing its antiviral drug forward, Durham-based Chimerix (Nasdaq:CMRX) has made a number of new additions to its board of directors and named a female board chair.
- GlobeNewswire•26 days ago
Chimerix Announces Martha J. Demski as Board Chair; Appoints New Members to Board of Directors
DURHAM, N.C., March 29, 2018-- Chimerix, a biopharmaceutical company developing novel antivirals to address unmet medical needs, today announced the appointment of Martha J. Demski as Chair of the Board ...
- American City Business Journals•last month
Durham pharma pushing to fight a common cold virus that's deadly to some patients
For Durham-based Chimerix, fighting a virus known to cause the common cold is not a task it takes lightly.
- GlobeNewswire•last month
The AdVance Study: a Landmark Natural History Study of Adenovirus in Allogeneic Hematopoietic Cell Transplant Shows Strong Correlation Between Disease Burden and Mortality Risk
DURHAM, N.C., March 19, 2018-- Chimerix, a biopharmaceutical company developing novel antivirals to address unmet medical needs, today announced data from AdVance, the first large, multi-center study of ...
- GlobeNewswire•2 months ago
Chimerix to Present at Cowen and Company 38th Annual Health Care Conference
DURHAM, N.C., March 07, 2018-- Chimerix, a biopharmaceutical company developing novel antivirals for the growing population of immunocompromised patients, today announced that M. Michelle Berrey, M.D., ...
- Zacks•2 months ago
Chimerix Q4 Loss Narrower Than Expected, Revenues Exceed
Chimerix (CMRX) makes progress in Q4 through advancement with lead product candidate, brincidofovir. Revenues decline from lower reimbursable expenses regarding BARDA developmental contract.
- GlobeNewswire•2 months ago
New Research: Key Drivers of Growth for Corcept Therapeutics, HubSpot, Tableau Software, Balchem, Steelcase, and Chimerix — Factors of Influence, Major Initiatives and Sustained Production
NEW YORK, March 02, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of CMRX earnings conference call or presentation 1-Mar-18 1:30pm GMT
Q4 2017 Chimerix Inc Earnings Call
- Associated Press•2 months ago
Chimerix reports 4Q loss
On a per-share basis, the Durham, North Carolina-based company said it had a loss of 41 cents. The results topped Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment ...
- GlobeNewswire•2 months ago
Chimerix Announces Fourth Quarter and Full Year 2017 Financial Results
-AdVance Data to be Presented at EBMT Annual Meeting-. -Oral and IV BCV Programs Remain on Track-- Conference Call at 8:30 a.m. ET Today-. DURHAM, N.C., March 01, 2018-- Chimerix, a biopharmaceutical company ...
- ACCESSWIRE•2 months ago
Chimerix, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / March 1, 2018 / Chimerix, Inc. (NASDAQ: CMRX ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 1, 2018 at 8:30 AM Eastern Time. To listen ...
- GlobeNewswire•2 months ago
Chimerix to Announce Fourth Quarter and Full Year 2017 Financial Results on March 1, 2018
DURHAM, N.C., Feb. 22, 2018-- Chimerix, Inc., a biopharmaceutical company developing novel antivirals for the growing population of immunocompromised patients, today announced that it will host a live ...
- Motley Fool•2 months ago
Could These 2 Biotech Stocks Really Double Your Money?
Analyst price targets for these two biotechs suggest they could double your money. Here's what you need to know.
- ACCESSWIRE•3 months ago
Wired News – Chimerix Announced Initiation of AdAPT Study for Oral Brincidofovir and Advancement of IV Brincidofovir to Phase-2 Studies
LONDON, UK / ACCESSWIRE / January 08, 2018 / Active-Investors.com has just released a free research report on Chimerix, Inc. (NASDAQ: CMRX ). If you want access to this report all you need to do is sign ...
- Thomson Reuters StreetEvents•5 months ago
Edited Transcript of CMRX earnings conference call or presentation 8-Nov-17 1:30pm GMT
Q3 2017 Chimerix Inc Earnings Call
- Simply Wall St.•5 months ago
Should You Buy Chimerix Inc (CMRX)?
Chimerix Inc (NASDAQ:CMRX), a biotechnology company based in United States, saw a decent share price growth in the teens level on the NasdaqGM over the last few months. As aRead More...
- Associated Press•5 months ago
Chimerix reports 3Q loss
On a per-share basis, the Durham, North Carolina-based company said it had a loss of 37 cents. The results surpassed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment ...
- ACCESSWIRE•5 months ago
Chimerix, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / November 8, 2017 / Chimerix, Inc. (NASDAQ: CMRX ) will be discussing their earnings results in their Q3 Earnings Call to be held on November 8, 2017 at 8:30 AM Eastern Time. ...
